Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

29.02B

Market cap29.02B

Price-Earnings ratio

21.32

Price-Earnings ratio21.32

Dividend yield

—

Dividend yield—

Average volume

952.31K

Average volume952.31K

High today

$200.99

High today$200.99

Low today

$193.20

Low today$193.20

Open price

$199.86

Open price$199.86

Volume

1.67M

Volume1.67M

52 Week high

$205.97

52 Week high$205.97

52 Week low

$121.05

52 Week low$121.05

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $196.58. The company's market cap stands at 29.02B, with a P/E ratio of 21.32.

As of 2026-06-18, Biogen(BIIB) stock has fluctuated between $193.20 and $200.99. The current price stands at $196.58, placing the stock +1.8% above today's low and -2.2% off the high.

The Biogen(BIIB)'s current trading volume is 1.67M, compared to an average daily volume of 952.31K.

During the past year, Biogen(BIIB) stock moved between $121.05 at its lowest and $205.97 at its peak.

BIIB News

Benzinga 6h

Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline

Biogen Inc. (NASDAQ:BIIB) on Wednesday agreed to acquire private biotechnology company RayThera Inc. for up to $1 billion. The company looks to further expand...

TipRanks 10h

Biogen Rated Buy as RayThera Acquisition Bolsters Immunology Pipeline and Long-Term Growth Prospects

In a report released today, Ami Fadia from Needham maintained a Buy rating on Biogen, with a price target of $255.00. Claim 55% Off TipRanks Unlock powerful inv...

TipRanks 10h

Biogen price target raised to $224 from $206 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Biogen (BIIB) to $224 from $206 and keeps an Equal Weight rating on the shares. The company presenting full Pha...

Analyst ratings

58%

of 38 ratings

Buy

57.9%

Hold

36.8%

Sell

5.3%

More BIIB News

TipRanks 14h

Biogen to Acquire RayThera in Up to $1B Deal to Expand Drug Pipeline

U.S.-based biotechnology company Biogen (BIIB) announced plans to acquire private biotech firm RayThera in a deal worth up to $1 billion, adding several promisi...

TipRanks 6d

Tvardi, Biogen, FuelCell, Magnite, Canadian Tire Trending

Analysts are intrested in these 5 stocks: ( (TVRD) ), ( (BIIB) ), ( (FCEL) ), ( (MGNI) ) and ( (CDNAF) ). Here is a breakdown of their recent ratings and the ra...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.